• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Pharmacology, Biochemistry and Behavior >Effects of acute low-dose combined treatment with rimonabant and sibutramine on appetite and weight gain in rats.
【24h】

Effects of acute low-dose combined treatment with rimonabant and sibutramine on appetite and weight gain in rats.

机译：利莫那班和西布曲明急性小剂量联合治疗对大鼠食欲和体重增加的影响。

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

In view of its potential advantages, drug polytherapy is currently attracting significant interest in the field of obesity research. In this context, concurrent manipulation of serotonergic and cannabinoid pathways in rodents has been found to reduce food and fluid intake in both an additive or synergistic manner. To further assess the value of this polytherapeutic approach, the current study examined the acute effects of low-dose combinations of the cannabinoid CB1 receptor antagonist/inverse agonist rimonabant (0.5 mg/kg) and the dual serotonin- and noradrenaline-reuptake inhibitor sibutramine (0.125 and 0.25 mg/kg) in male rats. Ethological analysis was used to generate comprehensive behavioural profiles, including the behavioural satiety sequence (BSS). Findings confirmed that, although neither drug given alone significantly altered food intake, feeding behaviour or weight gain, rimonabant per se tended to reduce consumption and time spent feeding while significantly increasing scratching and grooming responses. However, none of these effects of the CB1 receptor antagonist/inverse agonist was significantly altered by the presence of either dose of sibutramine. In striking contrast to recent reports of acute low-dose interactions (enhanced appetite suppression and reduced side-effects) between rimonabant and naloxone, present results would not appear to support the clinical potential of rimonabant/sibutramine polytherapy for obesity.
机译：考虑到其潜在的优势，药物多疗法目前在肥胖症研究领域引起了极大的兴趣。在这种情况下，已经发现在啮齿动物中同时操纵血清素能和大麻素途径可以以累加或协同方式减少食物和液体的摄入。为了进一步评估这种多药疗法的价值，本研究研究了低剂量大麻素CB1受体拮抗剂/反向激动剂利莫那班（0.5 mg / kg）以及5-羟色胺和去甲肾上腺素再摄取抑制剂西布曲明（ 0.125和0.25 mg / kg）。行为学分析用于生成综合的行为概况，包括行为饱腹感序列（BSS）。研究结果证实，尽管单独使用两种药物都不会显着改变食物摄入，进食行为或体重增加，但利莫那班本身往往会减少进食量和进食时间，同时显着增加抓挠和修饰反应。但是，无论哪种剂量的西布曲明的存在，都不会显着改变CB1受体拮抗剂/反向激动剂的这些作用。与最近有关利莫那班和纳洛酮之间急性低剂量相互作用（增强食欲抑制和副作用减少）的报道形成鲜明对比的是，目前的结果似乎不能支持利莫那班/西布曲明多联疗法在肥胖症中的临床潜力。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号